Literature DB >> 11413862

Effect of omeprazole on the pharmacokinetics of sustained-release carbamazepine in healthy male volunteers.

R K Dixit1, A B Chawla, N Kumar, S K Garg.   

Abstract

The present study shows the effect of omeprazole administration on the pharmacokinetics of a sustained-release preparation of carbamazepine in healthy male volunteers. Multiple dose administration of omeprazole increased the Cmax, AUC0-infinity and elimination half life (t1/2e) of carbamazepine. The results suggest that drug monitoring should be carried out when carbamazepine is coadministered with omeprazole.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11413862     DOI: 10.1358/mf.2001.23.1.619178

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  7 in total

1.  Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions.

Authors:  Yoshiyuki Shirasaka; Jennifer E Sager; Justin D Lutz; Connie Davis; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2013-04-25       Impact factor: 3.922

Review 2.  Drug-drug interaction profiles of proton pump inhibitors.

Authors:  Ryuichi Ogawa; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2010-08       Impact factor: 6.447

Review 3.  Pharmacokinetics of proton pump inhibitors in children.

Authors:  Catherine Litalien; Yves Théorêt; Christophe Faure
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  An Open Label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect, and Dose Proportionality of CC-292, a Potent and Orally Available Bruton's Tyrosine Kinase Inhibitor.

Authors:  Yiming Cheng; Liangang Liu; Yongjun Xue; Simon Zhou; Yan Li
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2022-06-03       Impact factor: 2.441

Review 5.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

6.  Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management.

Authors:  Wei Li; Su Zeng; Lu-Shan Yu; Quan Zhou
Journal:  Ther Clin Risk Manag       Date:  2013-05-27       Impact factor: 2.423

7.  Effect of esomeprazole on the pharmacokinetics of carbamazepine.

Authors:  Bikash Medhi; Pawan K Singh; Ajay Prakash; Pramod Avti
Journal:  Indian J Pharmacol       Date:  2011-02       Impact factor: 1.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.